Comparison of test performance of commercial anti-SARS-CoV-2 immunoassays in serum and plasma samples.

ABSTRACT:

Background

For epidemiologic, social and economic reasons, assessment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection prevalence and immunity are important to adapt decisions to current demands. Hence, immunoassays for detection of anti-SARS-CoV-2 antibodies are introduced rapidly without requiring FDA emergency use authorization approval. Thus, evaluation of test performance predominantly relies on laboratories. This study aimed to evaluate the test performance of recently launched commercial immunoassays in serum and plasma samples.

Methods

51 serum samples from 26 patients with confirmed SARS-CoV-2 infection after end of quarantine and 25 control patients were analyzed using anti-SARS-CoV-2 IgG immunoassays from Roche, Euroimmun and Epitope to as

SUBMITTER: Haselmann V 

PROVIDER: S-EPMC7343640 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature